News

This approval marks a critical step for the company in expanding the application of its innovative technology. The Nanoknife IRE platform is designed to ablate targeted tissue with precision electric field energy while maximizing the protection of surrounding healthy structures. The Relief study for BPH will evaluate the safety and preliminary efficacy of this platform as a potential minimally invasive treatment option.Benign prostatic hyperplasia is a common, age-related male urinary system condition that can result in lower urinary tract symptoms, significantly affecting patients’ quality of life. Current standard treatments include medication and more invasive surgical procedures. If the study results are positive, Nanoknife IRE technology may offer patients a new treatment option that could be less traumatic.Obtaining IDE approval enables AngioDynamics to initiate patient recruitment for this clinical study in the United States. The study’s progress will be closely watched by the medical community and investors, as it may open new market opportunities for the company and validate the potential application of its technology platform in the urology field.

US stock futures saw little short-term volatility, with Nasdaq 100 Index futures maintaining a gain of about 0.6%. The yield on the US 10-year Treasury bond showed little short-term fluctuation and is currently quoted at 4.440%. Spot gold experienced a slight short-term increase, currently quoted at $4327.37 per ounce.

This transaction not only consolidates the company's market position in the energy sector, but also significantly enhances its short-term cash flow expectations. Market analysts believe that the signing of this contract demonstrates Vivakor's key role in the crude oil supply chain and may have a positive impact on its future stock price performance.